Pharmacology/Pharmaceutical Industry | Page 25 of 172 | Links Medicus Content Curation & Alerts in Medicine

Comparative safety of BNT162b2 and mRNA-1273 vaccines in a nationwide cohort of US veterans.

14 Jun, 2022 | 11:08h | UTC

Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans – JAMA Internal Medicine

Commentary: Few differences in safety profiles of Moderna, Pfizer COVID-19 vaccines – Harvard T.H. Chan School of Public Health

Commentary on Twitter

1/
TODAY: We compared the safety of #COVID19 mRNA vaccines in the largest healthcare system in the US.

TAKE-HOME MESSAGE: Both Moderna and Pfizer vaccines are quite safe. If interested in vaccination, you can confidently use whichever one is available.https://t.co/fFIlXwH5Qv

— Miguel Hernán (@_MiguelHernan) June 13, 2022

Consensus Recommendations: How-to guide for medication reviews in older adults with cancer.

14 Jun, 2022 | 10:58h | UTC

How-to guide for medication reviews in older adults with cancer: A Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative – Journal of Geriatric Oncology

Cohort Study: Long-term risk of overdose or mental health crisis after opioid dose tapering.

14 Jun, 2022 | 10:53h | UTC

Long-term Risk of Overdose or Mental Health Crisis After Opioid Dose Tapering – JAMA Network Open

Editorial: New Data on Opioid Dose Reduction—Implications for Patient Safety – JAMA Network Open

News Release: Increased overdose and mental health risks persist two years after opioid dose reduction – UC Davis Center for Healthcare Policy and Research

BSH guideline for the hematological management of major hemorrhage.

13 Jun, 2022 | 10:53h | UTC

A guideline for the haematological management of major haemorrhage: a British Society for Haematology Guideline – British Journal of Haematology

RCT: Intramuscular tixagevimab–cilgavimab may benefit non-hospitalized unvaccinated adults with Covid-19.

13 Jun, 2022 | 10:39h | UTC

Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial – The Lancet Respiratory Medicine

Commentaries:

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID – News Medical

Expert reaction to results of the TACKLE Phase 3 trial of Evusheld (tixagevimab and cilgavimab) for treating early COVID-19 in outpatients – Science Media Centre

Commentary on Twitter

NEW—A single intramuscular tixagevimab–cilgavimab dose provided protection against progression to severe COVID-19 or death vs placebo in unvaccinated individuals

TACKLE trial from Prof Hugh Montgomery & colleagues https://t.co/M9LENFsA2C pic.twitter.com/Aon4wJsBOi

— The Lancet Respiratory Medicine (@LancetRespirMed) June 8, 2022

SGLT2 inhibitor reduces the risk of hyperkalemia in patients with heart failure.

13 Jun, 2022 | 07:52h | UTC

Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled – European Heart Journal

Editorial: Emerging role for SGLT2 inhibitors in mitigating the risk of hyperkalaemia in heart failure

Commentary on Twitter

More evidence that SGLT2i ⬇️ hyperK, this time in heart failure

Empagliflozin reduces:
– K>6.0: HR 0.62 95% CI 0.48–0.81
– Investigator reported hyperK or K binders, HR 0.82 95% CI 0.71-0.95
– Effect modified by GFR – larger in CKD
– Regardless of MRAshttps://t.co/t4T7II1G8p pic.twitter.com/RP1EUKXHyV

— Brendon Neuen (@brendonneuen) June 12, 2022

Under a https://creativecommons.org/licenses/by-nc/4.0/ license

Cohort Study: Long-term outcomes of early use of long-acting injectable antipsychotics in schizophrenia.

13 Jun, 2022 | 07:46h | UTC

Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia – The Journal of Clinical Psychiatry (link to abstract – $ for full-text)

Commentary: Patients With Schizophrenia Switched Early to LAIs Show Markedly Better Long-Term Outcomes – Psychiatric News Alert

Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis – The Lancet (link to abstract – $ for full-text)

Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre–post studies – The Lancet Psychiatry (link to abstract – $ for full-text)

Effect of Long-Acting Injectable Antipsychotics vs Usual Care on Time to First Hospitalization in Early-Phase Schizophrenia: A Randomized Clinical Trial – JAMA Psychiatry

Systematic Review: Oxycodone for cancer‐related pain.

13 Jun, 2022 | 07:37h | UTC

Oxycodone for cancer‐related pain – Cochrane Library

Summary: Oxycodone for cancer-related pain in adults – Cochrane Library

Retrospective Cohort Study: Incidence of major adverse cardiac events with immune checkpoint inhibitors.

13 Jun, 2022 | 07:32h | UTC

Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Institute—Cancer Therapy Evaluation Program – Journal of Clinical Oncology

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment – Journal of the American Heart Association

Cardiotoxicity of immune checkpoint inhibitors – ESMO Open

Cardiotoxicity from immune checkpoint inhibitors – IJC Heart & Vasculature

Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology – Journal of the Formosan Medical Association

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock – JACC: CardioOncology

Comparison of strategies to conserve iodinated intravascular contrast media for computed tomography during a shortage.

10 Jun, 2022 | 11:21h | UTC

Comparison of Strategies to Conserve Iodinated Intravascular Contrast Media for Computed Tomography During a Shortage – JAMA (free for a limited period)

News Release: Amid Global Shortage, Study Shows How to Cut Contrast Dye Use 83% – University of California, San Francisco (UCSF)

Commentary on Twitter

This modeling study estimated that intravenous contrast use for CT scans could be reduced by approximately 80% by using a combination of dose-reduction strategies. https://t.co/hlnvkdEECS

— JAMA (@JAMA_current) June 9, 2022

[News release – not published yet] Women not being routinely informed that a common anesthetic may lessen contraception effectiveness, doctors warn.

9 Jun, 2022 | 11:31h | UTC

Women not being routinely informed that a common anesthetic may lessen contraception effectiveness, doctors warn – The European Society of Anaesthesiology and Intensive Care (ESAIC)

Commentary: Women in UK ‘seldom’ told drug used in surgery can impede contraception – The Guardian

Review: Deprescribing in palliative cancer care.

9 Jun, 2022 | 11:28h | UTC

Deprescribing in Palliative Cancer Care – Life

Statement on initial antimicrobial treatment of sepsis.

8 Jun, 2022 | 11:17h | UTC

Statement on initial antimicrobial treatment of sepsis – Faculty of Intensive Care Medicine

Commentary on Twitter

🚨Statement on initial antimicrobial treatment of sepsis🚨

Full statement and documents available➡️ https://t.co/jWexX1VDDd @AoMRC pic.twitter.com/kQdJrZ2hOA

— FICMNews (@FICMNews) June 4, 2022

Why drug delivery is the key to new medicines.

8 Jun, 2022 | 10:51h | UTC

Why drug delivery is the key to new medicines – Nature Medicine

Combination anti-HIV antibody infusions suppress virus for prolonged period.

7 Jun, 2022 | 11:45h | UTC

News Release: Combination anti-HIV antibody infusions suppress virus for prolonged period – National Institutes of Health

Original Study: Combination anti-HIV antibodies provide sustained virological suppression – Nature

Commentaries on Twitter

Still don't get the enthusiasm for HIV Rx with bNAbs.
Compared to existing antivirals, they have:
– more baseline resistance
– the need to scale up new resistance tests
– more resource requirements (IV administration)
– … and, if like other monoclonals, $$$
What am I missing? https://t.co/7WZmIjutwE

— Paul Sax (@PaulSaxMD) June 1, 2022

This is a wonderful advance.

"Our data demonstrate that combination therapy with broadly neutralizing monoclonal antibodies can provide long-term virological suppression without antiretroviral therapy in individuals with HIV"https://t.co/DKNVSlg3mC

— Michael Worobey (@MichaelWorobey) June 2, 2022

#ADA2022 – RCT: Once-weekly dulaglutide for the treatment of youths with type 2 diabetes.

6 Jun, 2022 | 11:57h | UTC

Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Once Weekly Drug Helps Control Pediatric Type 2 Diabetes – American Diabetes Association

Commentary on Twitter

Trial compared once-weekly dulaglutide with placebo for glycemic control in youths with type 2 diabetes who may have been receiving metformin or basal insulin. Dulaglutide was superior at 26 weeks. #ADA2022 https://t.co/P6PubXvHOR pic.twitter.com/1JPIT5IyTe

— NEJM (@NEJM) June 4, 2022

Maternal vaccination: a review of current evidence and recommendations.

3 Jun, 2022 | 11:40h | UTC

Maternal vaccination: a review of current evidence and recommendations – American Journal of Obstetrics & Gynecology

Commentary on Twitter

AJOG Expert Review: Maternal vaccination: a review of current evidence and recommendations – Placental transfer of IgG antibodies from maternal to fetal circulation https://t.co/yd3DQpwSoD pic.twitter.com/obicClLhzC

— AJOG (@AJOG_thegray) April 1, 2022

Nationwide cohort study: Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer.

3 Jun, 2022 | 11:10h | UTC

Association between medical androgen deprivation therapy and long-term cardiovascular disease and all-cause mortality in nonmetastatic prostate cancer – International Journal of Cancer

Commentary: ADT for Prostate Cancer: What’s the Risk on the Heart? – Medscape (free registration required)

M-A: Oral Janus kinase inhibitors in the treatment of atopic dermatitis.

3 Jun, 2022 | 10:49h | UTC

Oral Janus kinase inhibitors in the treatment of atopic dermatitis: A systematic review and meta-analysis – Skin Health and Disease

Commentary: Systematic Review Suggests Oral JAK Inhibitors Effective in AD – HCP Live

M-A: Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response.

2 Jun, 2022 | 10:32h | UTC

Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis – Journal of Affective Disorders (link to abstract – $ for full-text)

Commentaries:

Antidepressants Have Small Effect Sizes for the Treatment of Major Depressive Disorder Among Children – Psychiatry Advisor

Antidepressant Effect Sizes Modest for Pediatric Major Depressive Disorder – Consultant360

Commentary on Twitter

MA: The SMD among all studies of antidepressants in C&A with MDD was 0.12 (0.08-0.17), a very small ES, lower than that seen in studies of adults with MDD. When the MA was limited to studies with a low mean placebo response, the SMD increased to 0.19 https://t.co/hPYvta4rgf

— P𝘧OL (@psychopharmacol) March 23, 2022

BSR guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs.

1 Jun, 2022 | 12:05h | UTC

The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs – Rheumatology

Executive summary: The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs – Rheumatology

Network Meta-Analysis: Effectiveness of heterologous and homologous covid-19 vaccine regimens.

1 Jun, 2022 | 12:00h | UTC

Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis – The BMJ

News Release: Three doses of the same or mixed covid jabs work equally well against infections – BMJ

Commentary: Three jabs best for preventing Covid infections, global analysis finds – The Guardian

Cohort Study: Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability.

1 Jun, 2022 | 11:44h | UTC

Association of Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability – JAMA Neurology

Author Interview: Prenatal Exposure to Antiseizure Medication With Risk of Autism and Intellectual Disability – JAMA

Commentaries:

Prenatal Exposure to Certain Antiseizure Meds Linked to Autism – HealthDay

Pregnant women who take common epilepsy drugs up to four times as likely to have child with autism or learning disabilities, study warns – Daily Mail

Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs – Neurology (link to abstract – $ for full-text)

Thirteen UK healthcare bodies launch ‘pragmatic’ guidance on valproate use – Royal College of General Practitioners

Association of Prenatal Exposure to Valproate and Other Antiepileptic Drugs With Risk for Attention-Deficit/Hyperactivity Disorder in Offspring – JAMA Network Open

Educational attainment of children born to mothers with epilepsy – Journal of Neurology, Neurosurgery, and Psychiatry (link to abstract – $ for full-text)

Commentary on Twitter

Nordic study of 4.5 million children found an association between prenatal exposure to topiramate and valproate and child intellectual disability and #autism. https://t.co/UH2THznPiV

— JAMA Neurology (@JAMANeuro) May 31, 2022